Deletion of the Gene Encoding Prostamide/Prostaglandin F synthase Reveals an Important Role in Regulating Intraocular Pressure

The prostaglandin F2 α (PGF2α) analogs are established as first line therapies for treating glaucoma. The selective FP receptor agonists were designed by virtue of the need to attenuate the ocular side effects produced by the naturally occurring prostanoid PGF2α [1-3]. Similarly, bimatoprost is an analog of PGF2α et hanolamide (prostamide F2α) [4, 5]. Both PGF2α and prostamide F2α are the products of identical biosynthetic pathways but differ with respect to their cyclo-oxygenase substrate. Thus, arachidonic acid is the primary precursor for PGF2α, whereas prostamide F2α is biosynthesized from the naturall y occurring mammalian endocannabinoid anandamide [6].

Source: Prostaglandins, Leukotrienes and Essential Fatty Acids - December 21, 2020 Category: Biomedical Science Authors: Jacques A Bertrand, David F Woodward, Joseph M Sherwood, Alice Spenlehauer, Cristoforo Silvestri, Fabiana Piscitelli, Vincenzo Di Marzo, Maya Yamazaki, Kenji Sakimura, Yoko Inoue, Kikuko Watanabe, Darryl R Overby Source Type: research